Q2 2025 Management View Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from commercial strength to ...

Now, in the wake of the FDA’s September conclusion that no changes were needed and that Nuplazid’s current label adequately describes its risks, the group is again arguing that Nuplazid was ...

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings ...

Nuplazid could offer an important new therapy for the hallucinations, illusions, and delusions experienced by many people with Parkinson's disease.

The Food and Drug Administration is re-evaluating the safety of a medication that was approved despite concerns that not enough was known about the drug’s risks.

Doctors and other experts tell CNN they worried that a new drug, Nuplazid, aimed at treating Parkinson’s disease patients with hallucinations was approved too quickly. Now hundreds of reports of ...

Nuplazid is available as 17mg strength tablets in 60-count bottles. For more information call (844) 422-2342 or visit Nuplazid.com.

Nuplazid is protected through a composition of matter patent that runs to 2021, as well as a use patent in PD to 2026. Investors have raised some concerns about safety, EU-market access and sales.

A cadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. The negative ...

Nuplazid recorded sales worth $353.4 million in the first nine months of 2021, reflecting an increase of 10.2% year over year. The company is also developing pimavanserin to treat other ...

Acadia Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval for Nuplazid, which the FDA said is the first drug it has approved to treat psychosis associated with Parkinson ...